Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals Inc. | Tegoprubart (AT-1501) - (BESTOW) | Kidney transplant rejection | Phase 2 | Data Released | Intravenous | Immunosuppressant |
| Eledon Pharmaceuticals Inc. | Tegoprubart (AT-1501) | Type 1 diabetes (islet cell transplantation) | Phase 2a | Trial Discontinued | Intravenous | Endocrinology |
| Eledon Pharmaceuticals Inc. | Tegoprubart (AT-1501) | Amyotrophic Lateral Sclerosis | Phase 2a | Trial Completed | Intravenous | Neurology |
| Eledon Pharmaceuticals Inc. | Tegoprubart (AT-1501) | IgA nephropathy (IgAN) | Phase 2a | Trial Discontinued | Intravenous | Immunology |
| Elevation Oncology Inc. | Seribantumab - (CRESTONE) | Solid Tumors | Phase 2 | Ongoing | Intravenous | Oncology |
| Eli Lilly and Company | Trulicity (dulaglutide) - (AWARD-PEDS) | Type 2 diabetes | Phase 3 | Subcutaneous | Endocrinology | |
| Eli Lilly and Company | Rezpegaldesleukin (LY3471851 or REZPEG) | Systemic lupus erythematosus (SLE) | Phase 2 | Trial Discontinued | Subcutaneous | Immunology |
| Eli Lilly and Company | Lebrikiuzmab | Pediatric atopic dermatitis | Phase 3 | Ongoing | Subcutaneous | Immunology |
